Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeksXiaomei Wang, Junqi Niu, Zhongfeng Wang et al.|International Journal of Infectious Diseases|2020Cited by 19
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 studyRui Hua, Junqi Niu, Fei Kong et al.|Journal of Viral Hepatitis|2022Cited by 7
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trialMingyuan Zhang, Junqi Niu, Jinlin Hou et al.|Journal of Infection|2025Cited by 6
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Infectious Diseases and Therapy|2023Cited by 6
LBP-014 HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb studyYanhang Gao, Junqi Niu, Xieer Liang et al.|Journal of Hepatology|2025Cited by 2